HanchorBio Partners with Bloomberg to Boost Pipeline & Strategy Execution

HanchorBio, Inc. , a global clinical-stage biotechnology company advancing next-generation immunotherapies for immuno-oncology and immune-related diseases, announced it has selected Bloomberg to support strategic decision-making across portfolio planning, pipeline development, competitive monitoring, business development, and capital markets activities.

Through access to Bloomberg's data and research content, including Bloomberg Intelligence's Disease dashboard via the Bloomberg Terminal, HanchorBio gains valuable insights into science, strategy and markets, supporting its understanding of biopharma innovation, competitive landscapes, partnerships, and global biotech trends across public and private companies.

"From the beginning, we have believed that biotechnology innovation requires both scientific originality and the ability to make better decisions as complexity increases," said Scott Liu, PhD, Founder, Chairman, and CEO of HanchorBio. "Our early work on HCB101 reflected that mindset in scientific design. We see the next step as extending that philosophy beyond molecule engineering into how we develop programs, prioritize opportunities, and build HanchorBio for long-term global growth."

"Scientific innovation alone is not enough," added Alvin Luk, PhD, MBA, CCRA, President & Chief Medical Officer (Group) and CEO (USA) of HanchorBio. "Clinical development, medical science, regulatory affairs, and strategic execution are increasingly interconnected. Our goal is to apply stronger intelligence and decision-making discipline across the full drug development lifecycle so that better analysis can translate into better decisions, stronger execution, and ultimately better outcomes for patients."

"In a fast-moving global biopharma environment, high-quality competitive and market intelligence is increasingly important for partnership strategy, portfolio positioning, and capital markets engagement," commented Yuehua Cong, PhD, Chief Business Officer of HanchorBio. "Access to Bloomberg's data and research content adds a valuable perspective by helping us monitor pipeline activity, licensing trends, investor dynamics, and broader industry developments."